These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20063996

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
    Nöteberg D, Hamelink E, Hultén J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A.
    J Med Chem; 2003 Feb 27; 46(5):734-46. PubMed ID: 12593654
    [Abstract] [Full Text] [Related]

  • 23. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A, Luque I, Kimura T, Kiso Y, Freire E.
    Biochemistry; 2002 Feb 19; 41(7):2273-80. PubMed ID: 11841219
    [Abstract] [Full Text] [Related]

  • 24. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
    Luksch T, Chan NS, Brass S, Sotriffer CA, Klebe G, Diederich WE.
    ChemMedChem; 2008 Sep 19; 3(9):1323-36. PubMed ID: 18752222
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC, Tiwari HK, Singla M, Rathi B, Sharma A, Mahiya K, Kumar M, Sinha S, Chauhan SS.
    J Biol Inorg Chem; 2010 Mar 19; 15(3):373-85. PubMed ID: 19946719
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
    Cunico W, Gomes CR, Facchinetti V, Moreth M, Penido C, Henriques MG, Varotti FP, Krettli LG, Krettli AU, da Silva FS, Caffarena ER, de Magalhães CS.
    Eur J Med Chem; 2009 Sep 19; 44(9):3816-20. PubMed ID: 19403210
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.
    Ersmark K, Nervall M, Hamelink E, Janka LK, Clemente JC, Dunn BM, Blackman MJ, Samuelsson B, Aqvist J, Hallberg A.
    J Med Chem; 2005 Sep 22; 48(19):6090-106. PubMed ID: 16162010
    [Abstract] [Full Text] [Related]

  • 39. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
    McKay PB, Peters MB, Carta G, Flood CT, Dempsey E, Bell A, Berry C, Lloyd DG, Fayne D.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3335-41. PubMed ID: 21531557
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.